Foghorn Therapeutics Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Foghorn Therapeutics

Access the complete profile.

Foghorn Therapeutics Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	100 - 500Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Address	500 Technology Square Suite 700 Cambridge, MA 02139

Note: Revenues for privately held companies are statistical evaluations.


Foghorn Therapeutics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Foghorn Therapeutics's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Foghorn Therapeutics is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Foghorn Therapeutics Annual Revenue and Growth Rate

Foghorn Therapeutics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$100 - $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Foghorn Therapeutics's revenues are gauged from an analysis of company filings.

Foghorn Therapeutics's Income Statement (based on Industry Averages)

Foghorn Therapeutics P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Foghorn Therapeutics is developing and marketing. Foghorn Therapeutics doesn't have any recent trademark applications, indicating Foghorn Therapeutics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
GENE TRAFFIC CONTROL Agents for medical and veterinary use, namely, pharmaceutical preparations for the treatment of diseases and disorders, namely, oncological, neurological, developmental, hematological, bone, respiratory, central nervous system, endrocrinological, metabolic, circulatory, gastroenterological, hormonal and diabetic disorders; pharmaceuticals, namely, epigenetic modulating agents and chromatin regulating agents to treat disease; diagnostic agents, preparations and substances for medical purposes; diagnostic preparation platforms for medicinal use featuring epigenetic modulating agents and chromatin regulating agents to treat disease	03/19/2018
GTC Agents for medical and veterinary use, namely, pharmaceutical preparations for the treatment of diseases and disorders, namely, oncological, neurological, developmental, hematological, bone, respiratory, central nervous system, endrocrinological, metabolic, circulatory, gastroenterological, hormonal and diabetic disorders; pharmaceuticals, namely, epigenetic modulating agents and chromatin regulating agents to treat disease; diagnostic agents, preparations and substances for medical purposes; diagnostic preparation platforms for medicinal use featuring epigenetic modulating agents and chromatin regulating agents to treat disease	03/19/2018
FOGHORN Agents for medical and veterinary use, namely, pharmaceutical preparations for the treatment of diseases and disorders, namely, oncological, neurological, developmental, hematological, bone, respiratory, central nervous system, endrocrinological, metabolic, circulatory, gastroenterological, hormonal and diabetic disorders; pharmaceuticals, namely, epigenetic modulating agents and chromatin regulating agents to treat disease; diagnostic agents, preparations and substances for medical purposes	11/16/2015

See all trademarks and details in the Full Report.

Market Share of Foghorn Therapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Foghorn Therapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Foghorn Therapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
BIOGEN	Cambridge, MA	100
SAREPTA THERAPEUTICS	Cambridge, MA	36
AMYLYX PHARMACEUTICALS	Cambridge, MA	11
BRAINTREE LABORATORIES	Braintree, MA	8
FOGHORN THERAPEUTICS	Cambridge, MA	5
RECRUITMENT STRATEGIES GROUP	Stoneham, MA	4

Future Competition: Foghorn Therapeutics's Fastest Growing Competitors

These companies are in the same general field as Foghorn Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)